苯磺酸左旋氨氯地平治疗原发性高血压的临床疗效及其对患者血管内皮功能的影响  

Clinical efficacy of sulfonic acid L-amiodipine and its influence on vascular endothelial function in treatment of primary hypertension

作　　者：梁友玲[1] 

机构地区：[1]山东省烟台市莱阳中心医院心内2区,265200

出　　处：《中国医师进修杂志》2013年第16期22-25,共4页Chinese Journal of Postgraduates of Medicine

摘　　要：目的评价苯磺酸左旋氨氯地平治疗原发性高血压的临床疗效及其对患者血管内皮功能的影响。方法200例原发性高血压患者（高血压组）按随机数字表法分为氨氯地平组（给予苯磺酸左旋氨氯地平治疗）和替米沙坦组（给予替米沙坦治疗），每组100例，连续治疗4周，检测治疗前后收缩压（SBP）、舒张压（DBP）、一氧化氮（N0）、内皮素（ET）．1和血脂水平，观察不良反应。并与80例健康查体者（对照组）进行比较。结果治疗前高血压组血脂、血压、NO及ET．1水平与对照组比较差异有统计学意义（P〈0．05）。氨氯地平组临床疗效总有效率为97．0％（97，100），替米沙坦组为88．0％（88／100），两组比较差异有统计学意义（r=5．838，P〈0．05）。氨氯地平组和替米沙坦组治疗后DBP、SBP水平与治疗前比较差异有统计学意义[（77．93±24．74）mmHg（1mmHg=0．133kPa）比（103．37±34．46）mmHg、（113．83±36．14）mmHg比（167．74±55．91）mmHg和（85．93±27．28）mmHg比（104．23±34．74）mmHg、（135．93±43．15）mmHg比（164．57±54．86）mmHg]（P〈O．05），并且氨氯地平组患者血压改善更显著，与替米沙坦组比较差异有统计学意义（P〈O．05）。氨氯地平组和替米沙坦组治疗后NO水平均较治疗前显著上升[（70．28±22．31）μmol／L比（50．97±16．99）μmol／L、（60．93±19．34）μmol／L比（51．15±17．05）μmol／L]，ET-1水平均较治疗前显著下降[（52．69±16．73）ng／L比（69．38±23．13）ng／L、（65．71±20．86）ng/L比（71．58±23．86）ng／L]，差异有统计学意义（P〈0．05），并且氨氯地平组患者NO、ET-1水平基本达到正常水平，与替米沙坦组比较差异有统计学意义（P〈0．05）。高血压组在治疗期间无不良反应发生。结论苯磺酸左旋氨氯地平治疗原发性高血压疗效显著，且安全可靠，可有�Objective To observe the clinical efficacy of sulfonic acid L-amlodipine and its influence on vascular endothelial function in treatment of primary hypertension. Methods Two hundred primary hypertension patients（hypertension group ） were divided into amlodipine group and telmisartan group by random digits table method with 100 cases each. The patients of amlodipine group were given the sulfonic acid L-amlodipine treatment, while the patients of telmisartan group were given the telmisartan treatment. The change of systolic blood pressure （SBP）, diastolic blood pressure（DBP）, nitric oxide （NO）, endothelin （ET）-I and blood lipid before and after treatment,and the adverse reaction were observed continuously for 4 weeks. Also 80 cases of healthy people （control group） were included as a comparative study. Results Before treatment, the lipid levels, blood pressure, NO, ET-1 of hypertension group showed significant difference compared with those of control group （P 〈0.05）. The effective rate of amlodipine group and telmisartan group was 97.0%（97/100） and 88.0%（88/100） respectively, and there was significant difference between two groups （X2 = 5.838, P 〈 0.05）. After treatment, DBP and SBP of amlodipine group and telmisartan group significantly improved, the difference was significant compared with that before treatment [ （77.93 ± 24.74） mm Hg （1 mm Hg =0.133 kPa） vs. （103.37 ±34.46） mm Hg, （113.83±36.14） mm Hg vs. （ 167.74 ± 55.91 ） mm Hg and （85.93 ± 27.28 ） mm Hg vs. （ 104.23± 34.74） mm Hg, （ 135.93 ±43.15 ） mm Hg vs. （164.57±54.86） mm Hg] （P 〈0.05）. The blood pressure of amlodipine group ameliorated more significantly,and the difference was significant compared with that of telmisartan group （P 〈 0.05）. NO and ET-1 of amlodipine group basically reached normal levels,and the difference was significantly compared with that of telmisartan group [（70.28±22.31） μmol/L vs. （50.97± 16.99） μmol/L, （60.93 ± 19.34

关 键 词：氨氯地平 高血压 内皮功能 

分 类 号：R544.1[医药卫生—心血管疾病]